DeepMed Research

Arcus Biosciences

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2015-01-01

Employees: 577

Market Cap: -

Website: http://www.arcusbio.com

Introduction: Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Clinical Trials

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: zimberelimab

First Posted Date: 2019-09-12

Last Posted Date: 2024-08-21

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 18

Registration Number: NCT04087018

Locations: 🇺🇸
Saint Francis Cancer Center, Greenville, South Carolina, United States
🇺🇸
Christiana Care Health System - Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸
Prisma Health, Greenville, South Carolina, United States

and more 6 locations

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer Metastatic
Non Small Cell Lung Cancer
Nonsquamous Nonsmall Cell Neoplasm of Lung
Sensitizing EGFR Gene Mutation

Interventions: Drug: Etrumadenant
Drug: Zimberelimab
Drug: Carboplatin
Drug: Pemetrexed
Drug: Pembrolizumab

First Posted Date: 2019-02-19

Last Posted Date: 2024-12-09

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 77

Registration Number: NCT03846310

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
🇰🇷
Bundang CHA Medical Center, Seongnam-si, Korea, Republic of
🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

and more 19 locations

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Phase 1

Completed

Conditions: Colorectal Cancer
GastroEsophageal Cancer

Interventions: Drug: etrumadenant
Drug: mFOLFOX

First Posted Date: 2018-10-25

Last Posted Date: 2024-05-24

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 44

Registration Number: NCT03720678

Locations: 🇺🇸
Carolina BioOncology Institute, Huntersville, North Carolina, United States
🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States
🇦🇺
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia

and more 21 locations

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Phase 1

Completed

Conditions: TNBC - Triple-Negative Breast Cancer
Ovarian Cancer

Interventions: Drug: Etrumadenant
Drug: nanoparticle albumin-bound paclitaxel (NP)
Drug: IPI-549
Drug: Pegylated liposomal doxorubicin (PLD)

First Posted Date: 2018-10-25

Last Posted Date: 2024-05-24

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 35

Registration Number: NCT03719326

Locations: 🇦🇺
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸
Texas Oncology, P.A. - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States

and more 24 locations

A Study to Investigate the Safety of AB680 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: AB680
Other: Placebo

First Posted Date: 2018-09-19

Last Posted Date: 2024-05-24

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 64

Registration Number: NCT03677973

Locations: 🇦🇺
Melbourne, VIC, Melbourne, Victoria, Australia

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Phase 1

Completed

Conditions: Solid Tumor, Unspecified, Adult

Interventions: Drug: Domvanalimab
Drug: Zimberelimab

First Posted Date: 2018-08-14

Last Posted Date: 2025-02-04

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 75

Registration Number: NCT03628677

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇦🇺
Tweed Hospital, Tweed Heads, New South Wales, Australia
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States

and more 7 locations

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer
Squamous Cell Carcinoma of the Head and Neck
Breast Cancer
Colorectal Cancer
Melanoma
Bladder Cancer
Ovarian Cancer
Endometrial Cancer
Merkel Cell Carcinoma
GastroEsophageal Cancer

Interventions: Drug: Etrumadenant
Drug: Zimberelimab

First Posted Date: 2018-08-14

Last Posted Date: 2024-05-24

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 48

Registration Number: NCT03629756

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇦🇺
Cabrini Health Limited, Malvern, Australia
🇺🇸
Scottsdale Healthcare Hospitals dba HonorHealth, Scottsdale, Arizona, United States

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy